Pitavastatin reduces lectin-like oxidized low-density lipoprotein receptor-1 ligands in hypercholesterolemic humans.
The aim of this study was to determine the impact of pitavastatin on low-density lipoprotein cholesterol (LDL-C) and lectin-like oxidized LDL receptor-1 (LOX-1) in patients with hypercholesterolemia. Twenty-five hypercholesterolemic patients (8 male, 17 female; age 66 +/- 13, 21-80 years) who had not received anti-dyslipidemic agents and had LDL-C levels of more than 160 mg/dL were examined. Biochemical factors were measured at baseline and after treatment with pitavastatin (2 mg/day) for 6 months. Serum levels of LOX-1 with apolipoprotein B-100 particle ligand and a soluble form of LOX-1 (sLOX-1) were measured by ELISA. All subjects completed the study with no adverse side effects. Total-C (268 +/- 26 vs. 176 +/- 17 mg/dL), LDL-C (182 +/- 21 vs. 96 +/- 14 mg/dL), and LOX-1 ligand (867 +/- 452 vs. 435 +/- 262 ng/mL) were reduced with pitavastatin treatment (P < 0.0001 for each). Significant decreases in triacylglycerols were noted (P < 0.0001), but there were no changes in high-density lipoprotein cholesterol. After 6 months, there were no significant changes in high-sensitivity CRP or soluble LOX-1. At baseline, there were no significant correlations between LOX-1 ligand and either LDL-C or sLOX-1. The decrease in LOX-1 ligand was not correlated with the decrease in LDL-C, but was correlated with the decrease in sLOX-1 (r = 0.47, P < 0.05). In conclusion, pitavastatin therapy had beneficial effects on markers of oxidative stress in hypercholesterolemic subjects. Serum levels of LOX-1 ligand may be a useful biomarker of the pleiotropic effects of statins.
Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Seta Tsukinowa, Otsu, Shiga 520-2192, Japan. tetsuyam@belle.shiga-med.ac.jp
Tetsuya
T
Matsumoto
Masatoshi
M
Fujita
Tatsuya
T
Sawamura
Akemi
A
Kakino
Yuko
Y
Sato
Yoshiko
Y
Fujita
Haruo
H
Matsuda
Mamoru
M
Nakanishi
Kagehiro
K
Uchida
Izuru
I
Nakae
Hiroshi
H
Kanda
Akira
A
Yoshida
Kunihisa
K
Miwa
Hideki
H
Hayashi
Kenichi
K
Mitsunami
Minoru
M
Horie
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000924:Anticholesteremic Agents / Q000494:pharmacology / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood / Q000378:metabolism; D008078:Cholesterol, LDL / Q000097:blood; D015536:Down-Regulation / Q000187:drug effects; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood* / Q000188:drug therapy; D008024:Ligands; D008297:Male; D008875:Middle Aged; D011804:Quinolines / Q000494:pharmacology* / Q000627:therapeutic use; D051127:Scavenger Receptors, Class E / Q000097:blood*; D055815:Young Adult
D000924:Anticholesteremic Agents; D015415:Biomarkers; D008078:Cholesterol, LDL; D008024:Ligands; D011804:Quinolines; D051127:Scavenger Receptors, Class E; C108475:pitavastatin